Actinium Pharmaceuticals to Present Early Phase 1 Data for ATNM-400 in Prostate Cancer at EANM
Bitget2026/10/15 12:34- Actinium Pharmaceuticals will present early Phase 1 results for prostate cancer therapy ATNM-400 on October 19, 2026, at EANM in Vienna.
- Initial clinical data support advancing the non-PSMA-targeted radiotherapy for metastatic castration-resistant prostate cancer.
- ATNM-400 targets patients with low or absent PSMA expression, including those whose disease resists PSMA-directed therapies.
- The ongoing first-in-human trial evaluates safety and drug distribution to guide dosing of the actinium-225 therapy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

Why Nintendo Stock Is One to Watch Ahead of the Holiday Season

A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.

Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.